Young breast cancer survivors can boost their chance of remaining cancer-free by inducing artificial menopause, a major Australian-led study has found.
The idea is to reduce levels of oestrogen, the female sex hormone known to fuel the re-growth of hormone-sensitive tumours, which account for about 80 per cent of breast cancers in under-50s.
Standard treatment for survivors is a drug called tamoxifen that suppresses the hormone.
However, researchers found that by adding ovarian suppression to this treatment, they were able to further reduce a patient's risk of tumour recurrence by 22 per cent over five years.
Four to five extra women out of every 100 treated would remain cancer-free under the new regimen, researchers led by Dr Prudence Francis of the Peter MacCallum Cancer Centre wrote in the New England Journal of Medicine on Friday.